Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alisrythm; DU 6552; Pilsinic; Pilzicainide; Rizmsat; Rizumcote; SUN 1165; SUN 1165i; Sunrhythm; Sunrythm; Tatsupilljin

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asubio Pharma
  • Developer Asubio Pharma; Daiichi Sankyo Company
  • Class 2 ring heterocyclic compounds; Acetanilides; Class Ic antiarrhythmics; Pyrrolidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias

Most Recent Events

  • 31 Dec 2007 Launched for Arrhythmias in South Korea (PO)
  • 31 Dec 2007 Registered for Arrhythmias in South Korea (PO)
  • 01 Apr 2007 Daiichi Asubio Pharma is now called Asubio Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top